DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
ALSO READ :
Geography Covered
• Global coverage
Wet Age-Related Macular Degeneration (Wet-AMD) Understanding
Wet Age-Related Macular Degeneration (Wet-AMD): Overview
Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10–20% of individuals, it progresses to the wet type. Wet AMD is less common but more severe than the dry type.
Wet AMD, also known as neovascular AMD or exudative AMD, is a form of retinal degeneration in which abnormal choroidal neovascularization occurs under the retina and macula lutea. Because these new blood vessels are abnormal, they tend to break, bleed, and leak fluid, damaging the macula and causing it to lift up and pull away from its base. This can result in a rapid and severe loss of central vision.
ALSO READ :
The complaints of a patient with wet AMD may vary from metamorphopsia, central or paracentral scotoma, to a sudden, nonspecific reduction in central vision. Common symptoms of wet AMD include: Distortion of straight lines (metamorphopsia), a blind spot or hole in one’s vision (scotoma), difficulty with adaptation to the dark.
Age-related macular degeneration is defined by fundus examination, but the diagnosis of AMD is typically based on age, clinical findings through various tests like Color fundus photography, Fluorescein angiography and/or Optical coherence tomography. Color photography and fluorescein angiography are done when findings suggest wet AMD. A simple test for daily monitoring of vision in patients with AMD is the Amsler grid. Anti-VEGF medications are the most effective and most common treatment for wet AMD. Patients with unilateral wAMD should take the daily nutritional supplements that are recommended for dry AMD to reduce the risk of AMD-induced vision loss in the other eye.
Report Highlights
ALSO READ :
http://www.marketwatch.com/story/june-2021-report-on-covid-19-global-usa-power-energy-storage-battery-market-overview-size-share-and-trends-2021-2026-2021-06-08
• The companies and academics are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet-AMD) R&D. The therapies under development are focused on novel approaches for Wet Age-Related Macular Degeneration (Wet-AMD).
Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs Chapters
This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ALSO READ :
Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs
• SOK583A1: Sandoz
Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).
It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz. In May 2021, Sandoz announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT—a clinical Phase III confirmatory efficacy and safety study.
• SB15: Samsung Bioepis
SB15 is being developed as a biosimilar to the reference product Eylea (aflibercept)—an anti-VEGF drug.
It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Samsung Bioepis. Samsung Bioepis announced in November 2019 that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept), in the US, Canada, Europe, Japan, and Australia.
Further product details are provided in the report……..
Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment
This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Wet Age-Related Macular Degeneration (Wet-AMD)
There are approx. 70+ key companies which are developing the Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e. Phase III include, Sandoz.
• Phases
DelveInsight’s report covers around 70+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.
Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights
• Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Wet Age-Related Macular Degeneration (Wet-AMD) Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
• How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?
• How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration (Wet-AMD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Sandoz
• Sam Chun Dang Pharm
• Samsung Bioepis
• Opthea Limited
• Luye Pharma
• Shanghai Henlius Biotech
• Generium Pharmaceuticals
• Bioeq GmbH
• Roche
• Chong Kun Dang Pharmaceutical
• Outlook Therapeutics
• Kodiak Sciences
• Amgen
• Qilu Pharmaceuticals
• Xbrane Biopharma
• Regenxbio
• Formycon
• Dobecure
• Gemini Therapeutics
• Isarna Therapeutics
• AngioLab Inc
• Alkahest
• Tyrogenex
• IVERIC bio (formerly Ophthotech Corporation)
• Tasly Pharmaceutical Group
• Ribomic
• Innovent Biologics
• Gemini Therapeutics
• GrayBug Vision
• Curacle
• Quark Pharmaceuticals
• Bio-Thera Solutions
• RemeGen
• Sinocelltech
• PanOptica
• Clearside Biomedical
• AsclepiX Therapeutics
• Feramda
• AiViva BioPharma
• Unity Biotechnology
• Kyowa Kirin
• Ocular Therapeutix
• Janssen Research & Development
• Huabo Biopharm
• EyePoint Pharmaceuticals
• Shanghai Biomabs Pharmaceutical
• Ashvattha Therapeutics
• Samjin Pharm
• Akari Therapeutics
• Eyevensys
• PharmAbcine
• Neurophth Therapeutics
• Ocugen
Key Products
• SOK583A1
• SCD411
• SB15
• OPT-302
• LY09004
• HLX04-O
• GNR-067
• FYB203
• Faricimab
• CKD-701
• ONS-5010
• KSI-301
• ABP 938
• BCD 300
• Xlucane
• RGX-314
• FYB201
• Etamsylate
• GEM-103
• ISTH0036
• ALS-L1023
• AKST4290
• Vorolanib (X-82)
• Zimura
• Sanhuangjingshimingwan
• RBM-007
• IBI302
• GEM103
• GB-102
• CU03
• PF-04523655
• BAT5906
• RC 28 E
• SCT510A
• PAN 90806
• CLS-AX
• AXT107
• AS101
• AIV007
• UBX1325
• KHK4951
• OTX-TKI
• AAVCAGsCD59
• HB002.1M
• EYP-1901
• CMAB818
• D-4517
• SJP1803/1804
• Nomacopan
• EYS609
• EYS809
• PMC-309
• PMC-403
• NFS-10
• OCU 200
Table of Contents :
Introduction
Executive Summary
Wet Age-Related Macular Degeneration (Wet-AMD): Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Wet Age-Related Macular Degeneration (Wet-AMD)– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Wet Age-Related Macular Degeneration (Wet-AMD) companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Wet Age-Related Macular Degeneration (Wet-AMD) Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
SOK583A1: Sandoz
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
ISTH0036: Isarna Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
UBX1325: Unity Biotechnology
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
EYS809: Eyevensys
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
Wet Age-Related Macular Degeneration (Wet-AMD) Key Products
Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs
Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers
Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion
Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views
Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
Appendix
Table 1 Total Products for Wet Age-Related Macular Degeneration (Wet-AMD)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Wet Age-Related Macular Degeneration (Wet-AMD)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
....contiued
Contact Details :
+44 203 500 2763
+1 62 825 80070
971 0503084105
Corner baths is perhaps the most intelligent way to save space while adding a unique character to your bathroom space.
All around us, it seems winter has made an earlier-than-expected arrival, making the appeal of a relaxing and luxurious hot bath all the more alluring.
With the cold season looming, the bathtub becomes an enticing and relaxing retreat that may just become your favourite new spot in the house.
In our previous Blog, we encouraged homeowners to make the most of the smaller bathroom in your house.
A corner bath is an excellent design choice that blends well into any bathroom space with a generous incentive of comfort, stylish looks and durability to match.The Benefits of investing in a Corner BathtubMaximise the Space in your BathroomMaking a small bathroom work can be frustrating, especially if you don’t know where to start.
A corner bathtub is a perfect cornerstone (pardon the pun!)
The use of leave management software in human resources is a growing necessity.
Managing leave time can be a tedious task for HR professionals, especially in industries that offer a variety of different employee leave types.Attempting to sort and manage different leave times and types for numerous employees is made easier with some of the leading leave management software options available on the market for HR professionals.Subscribe free now to get more technological updates!
https://is.gd/NBPmt3 Leave management software for HRBelow are the top 7 leave management software that HR professionals in small to midsize businesses are benefiting from in 2019.1.
PaycorFor the growing industries that need the ability to adjust employee data with leave management software, Paycoroffers a variety of features that can be manipulated to fit your company needs.
CuckooTechWith its self-service feature, CuckooTech is an employee leave software that allows employee scheduling and payroll to be modified based on the collected leave data that is inputted into the software.
From annual, vacation, or sick leave, to comp leave or PTO time depending on how it is coded on the timesheet, professionals can organize and monitor numerous employees with this leave tracking software.
AOL is one of the most widely used email services all around the world.
Despite providing email services, AOL also allows users to access trending videos, browse the internet, play games, and do other online stuff.
By downloading the AOL App for Windows 10, a user can check their emails, stay up to date with the latest news, manage contacts, and do other activities.
If you are also looking forward to using the AOL services, this post can help you.Here, we are sharing some simple instructions that can help you to download the AOL mail app for Windows 10 computers.AOL app for windows 10: Easy InstructionsWith all in one AOL desktop application, you can browse data, send or receive emails, search content, and do the other online tasks.
To get the latest version of the AOL mail app for Windows 10, you need to proceed with the simple guidelines we are sharing below.But, before you download the application, it is highly recommended to check for the system requirements to download AOL desktop gold for Windows 10 PC:• Updated operating system.• Minimum 266MHz processor.• 1024X768 aur better screen resolution.• 1 GB RAM and 512 MB hard disk space.• Strong and stable internet connection.For installing the AOL mail app for Windows 10 PC, you need to make sure that your system does not have any conflicting programs installed in it.
Also, make sure that you have a valid AOL subscription.Now that the above requirements have been fulfilled, you can proceed next in following the simple instructions to install the AOL desktop gold application on your Windows 10 system:• Open any web browser on your computer.• Visit AOL’s official website and download the AOL desktop gold installation file.• Once the file is downloaded, with the download folder and click on the run button to run the installation file.• Proceed with the Windows installation instructions to complete the setup process.• After this, you can see the AOL desktop gold icon appearing on your Windows 10 computer.• Click on the icon and start using the able services.• Install AOL app for Windows 10 using Windows store:• Open the windows store on your computer.• Click on the search icon to find the AOL app for Windows 10.• Choose the “Apps” option for exploring more applications.• Once you find the application, click on the button to install it on your system.• Open the application after installation.• Proceed with the onscreen step for the installation.• So, this is how you can complete the AOL mail app for Windows 10 download and installation on your system without any trouble.
No one really likes ads, except perhaps the marketers and creatives responsible for making them.
The fact is, ads are annoying, especially the interstitials, banners, and video ads that make it virtually impossible to read an article or watch a video that has been clicked on.
This makes it no surprise that the adoption and use of ad blockers have skyrocketed recently.Another step that Google has taken to help provide a more user-friendly experience is the recently announced “ad filter” that is available through Chrome.
https://is.gd/VLQMdJTypes of Native AdsOne of the first things to understand is the native advertising options available today.
In-Feed AdsThis is, perhaps, the most popular way native advertising is used.
These can take one of two forms – in-feed promotions or sponsored content.Sponsored content takes the function and form of other content that looks “normal” in a person’s feet.
Last month, the NRCC (National Republican Congressional Committee) brought in $7 million in fundraising as the reelection arm of the House GOP continues to build resources as part of its mission to regain the chamber’s majority in the 2022 midterm elections.
The latest figures from the NRCC shared data with a news channel on Thursday.
It says the committee has hauled in $86.3 million so far this year.
It is more than which raised during all of 2019, the last off-election year.
The NRCC said that the committee had only raised $48.6 million.
And it also noted that last month’s $7 million hauls are its best July fundraising in an off-year and that it’s the NRCC’s fifth straight record-breaking fundraising month.
